Skip to search formSkip to main contentSkip to account menu

PI3K-delta Inhibitor TGR-1202

Known as: TGR-1202 
An orally bioavailable, selective inhibitor of the delta isoform of the 110 kDa catalytic subunit of class I phosphoinositide-3 kinases (PI3K) with… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Introduction: Inhibition of PI3Kδ (idelialisib, TGR-1202) has been reported as having limited clinical benefits for the treatment… 
2017
2017
Background: Although kinase inhibitor (KI) therapies such as ibrutinib are generally well tolerated, intolerance is the most… 
2016
2016
Phosphoinositide 3-kinase (PI3K) and the proteasome pathway are both involved in activating the mechanistic target of rapamycin… 
2014
2014
Introduction: The phosphatidylinositol 3-kinase (PI3K) pathway is consistently activated in relapsed/refractory Hodgkin lymphoma… 
2013
2013
P753 BACKGROUND TGR-1202 Presented at the 18th Congress of the European Hematology Association (EHA) June 13 – 16, 2013…